Objective: To analyze the efficacy and safety of entecavir (ETV) treatment for up to 5 years in
nucleos (t) ide-naïve chronic hepatitis B patients in real life. Methods: We retrospectively …

Objective To evaluate the virological, serological and biochemical outcomes of 3 years of
entecavir (ETV) treatment in nucleoside-naive chronic hepatitis B patients. Methods This …

HKU Scholars Hub: Outcome of 4-year treatment of entecavir for treatment-naive chronic
hepatitis B Skip navigation HKU Login Guest Login Home Publications Researchers Staff …

Background: Entecavir (ETV) demonstrated superior virologic and biochemical benefit
compared to lamivudine (LVD) after 48 weeks of therapy in nucleoside-naïve chronic …

Objective. Partial virologic response (PVR) in chronic hepatitis B (CHB) patients during
antiviral therapy is associated with an increased risk of occurrence of viral resistance and …

Purpose To compare the efficacy of entecavir (ETV) monotherapy up to 4 years in nucleos (t)
ide analog (NA)-experienced and-naïve subjects. Methods One hundred sixty NA …

Background Entecavir, a drug with high potency and genetic barrier against hepatitis B virus,
was believed to become very effective in reducing the hepatitis B burden in India. Long-term …

Methods Chronic hepatitis B patients treated with ETV (0.5 mg/day) for at least 1 year were
enrolled retrospectively. PVR was defined as a decrease in hepatitis B virus (HBV) DNA titer …

Background & Aims: Entecavir demonstrated superior benefit to lamivudine at 48 weeks in
nucleoside-naive patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B …

BACKGROUND/AIMS: The clinical course of patients with insufficient virologic suppression
diagnosed with chronic hepatitis B undergoing entecavir therapy is unclear. METHODS: We …